AORTICLAB is an innovative start-up that offers high-tech cutting-edge solutions in the treatment of severe aortic stenosis:
- to raise safety standards for all patients
- to offer a clinical solution even for patients currently considered untreatable
- to provide accessible, sustainable solutions for all patients
AorticLab is there for anyone seeking a new, effective and reliable procedure that is both less invasive and more sustainable, with lower risks
The profound value of each person’s story, the immense wealth of emotions that our loved ones reserve for us and sheer respect for all aspects of life are the inspiration that has driven us since day one. It is why our research and innovation path, state-of-the-art technology and protection walk hand in hand. The effectiveness of our solutions and the achievement of lower risk for patient and clinical staff are actually two parallel paths with a common endpoint: patients’ safety and quality of life.
Pursuing this objective has brought us to the launch of products for safer and less invasive treatment of aortic stenosis, offering sustainable heart interventional solutions.
Because a person we love might be the owner of a beating heart that until now could not be treated
AORTICLAB was founded in 2016 by experienced MedTech professionals and physicians intending to develop new technologies for cardiovascular procedures. AORTICLAB was financed in three stages by a group of Investors in the Medtech industry. In the last two years there has been an increase in investment and in staff numbers. Today AORTICLAB employs eighteen people and plans to invest six million euros in 2021.
- Passion and courage guide us in the research and discovery of innovations to enhance general well being.
- Knowledge and progress allow us to improve technological results by meeting the needs of the community.
- A serious professional approach means we require reliability in our products while respecting corporate integrity.
YOUNG ENERGIES, PROVEN EXPERIENCE
We are a young business, founded on extensive experience.
Our people are a balanced mix of women and men who share a belief in meritocracy and deep commitment, without any other distinctions.
We are a cohesive team, driven by passion and by a pioneering approach.
35+ years experience in preclinical (R&D and RA) and clinical activities for cardiovascular devices as VP Clinical Affairs (Sorin, Edwards LS).
35 + years experience as Controller/CFO in the Medical Devices industry (Sorin, DiD)
Cardiac Surgeon at Lyon Univ. Hosp. since 2006. Pioneer and KOL in minimally invasive cardiac surgery
20+ years experience in CV devices design and manufacturing Past R&D/QC director in Sorin/Livanova heart valve division
R&D Project Leader
YI PENG BAI
Maria Chiara Palmieri
|CARLO VANOLI||Chairman||Past top executive in MedTech companies, 30+ years industry experience, co-founder of Medeor Associates, investor in AL since first seed round|
|FRANCO OSTA||CEO, Founder||35+ years experience as Controller/CFO in the Medical Devices industry (Sorin), CiD founder in management buy out procedure|
|ENRICO PASQUINO||CSO, Founder||35+ years experience in preclinical (R&D and RA) and clinical activities for cardiovascular devices as VP Clinical Affairs (Sorin, Edwards LS)|
|BIAGIO CALÒ||Board Member||35+ years experience manager in Olivetti Group; CTS Cashpro founder|
|GIORGIO CHIEREGATTI||Board Member||35+ years experience in the IVD/Imaging Industry, Business Unit Head in Sorin Group, co-founder of Gipharma|
|STEFANO OSTA||Board Member||Project Management - MSC in Business Economics (Bocconi University and Polytechnic of Lugano)|
|CLAUDIO ZUCCOLOTTO||Board Member||Former Executive in Accenture Strategic Services and Managing Director in Pharma Packacing industry for a decade. IAG Champion for medical devices area|
INVESTORS & PARTNER
Our Investors and Partners endorse our vision and group identity pillars.
We have Investors devoted to technology edge innovation and ready to support the next generation cardiology devices. We are looking for companies with the same DNA we have, developing the future of the cardiovascular procedures.